Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis

Paul O'Connor, David Miller, Katherine Riester, Minhua Yang, Michael Panzara, Catherine Dalton, Katherine Miszkiel, Omar Khan, George Rice, William Sheremata, G. J. Barker, D. G. MacManus, C. Webb, C. Middleditch, S. Lewis, T. Pepple, E. Riddle, C. Coombs, M. Agius, D. RichmanJ. Adams, M. Buonocore, J. Al-Omaishi, K. Markopoulou, K. Healey, P. Sorensen, D. Bates, J. Forsyth, J. Curlis, P. English, L. Blumhardt, V. Orpe, T. Jaspen, J. Bowen, M. Chang, H. Lew, M. Burke, T. Richards, J. L. Carter, D. Dodick, J. Takata, M. Malikowski, K. Nelson, D. A H Cross, J. Trotter, D. Derrington, J. Lauber, C. Martinez, G. Foster, T. Conturo, V. Devonshire, J. Oger, L. Wang, W. Morrison, L. Costley, C. Hawkins, C. Mathews, C. Gibson, J. Hebert, I. Rozentsvit, L. Capolino, J. P. Kelly, M. Kaufman, S. Putman, A. Diedrich, R. Follmer, S. Dombrowski, C. Graves, B. Harwick, A. C. Tselis, M. Din, C. Caon, M. Cochran, Z. Latif, R. P. Lisak, M. Zvartau-Hinds, L. Metz, J. Scott, D. Patry, M. Yeung, J. Heuser, C. Wallace, S. Curtis, A. Miller, E. Drexler, M. J. Keilson, K. Bruining, A. Schneider, R. Wolintz, L. Sciarra, H. Oltazewska, R. S. Murray, A. Bowling, R. E. Kramer, K. Bracht, C. O'Brien, L. Seeberger, J. Leitch, E. Prenger

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Background: Natalizumab, a humanized monoclonal IgG4 antibody, is an α4-integrin antagonist, which inhibits the migration of inflammatory cells into the central nervous system, a key pathogenic mechanism in multiple sclerosis (MS). In a six month, phase II clinical trial of patients with relapsing MS, natalizumab significantly reduced the formation of new gadolinium-enhanced (Gd+) lesions and the number of clinical relapses. Objective: To investigate the relationship of historical relapse rate and new Gd+ lesion number with subsequent MS disease activity and natalizumab treatment in the phase II study. Methods: Patients who participated in the phase II study were stratified into subgroups according to: (i) the number of relapses in the two years prior to entry into the study: 2 relapses (n = 108), 3 relapses (n = 57), and >3 relapses (n = 48); (ii) the number of new Gd+ lesions at baseline (Month 0): 0 (n = 129), 1-2 (n = 50), and >2 (n = 33). Relapses and new Gd+ lesions during the treatment phase of the trial were determined and compared for each subgroup. Results: Both the prestudy relapse rate and number of new Gd+ lesions at baseline were related to the subsequent risk of a relapse; baseline number of Gd+ lesions was related to the likelihood of subsequent new Gd+ lesion formation. There was a lower proportion of subjects with an on-study relapse and fewer new Gd+ lesions in all natalizumab-treated subgroups when compared with their placebo counterpart; the difference was most apparent in the subgroups of patients with >3 relapses in the two years prior to study entry and >2 new Gd+ lesions at Month 0. Conclusions: There was a lower proportion of subjects with an on-study relapse in natalizumab-treated patients, particularly in those with a more active disease at study entry. Larger ongoing phase III studies will allow more definitive investigation of these preliminary subgroup findings.

Original languageEnglish
Pages (from-to)568-572
Number of pages5
JournalMultiple Sclerosis
Volume11
Issue number5
DOIs
StatePublished - Oct 1 2005

Fingerprint

Multiple Sclerosis
Recurrence
Natalizumab
Antibodies, Monoclonal, Humanized
Phase II Clinical Trials
Gadolinium
Integrins
Cell Movement
Central Nervous System
Immunoglobulin G
Placebos

Keywords

  • Gadolinium-enhancing lesions
  • Natalizumab
  • Relapsing MS

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

O'Connor, P., Miller, D., Riester, K., Yang, M., Panzara, M., Dalton, C., ... Prenger, E. (2005). Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis. Multiple Sclerosis, 11(5), 568-572. https://doi.org/10.1191/1352458505ms1205oa

Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis. / O'Connor, Paul; Miller, David; Riester, Katherine; Yang, Minhua; Panzara, Michael; Dalton, Catherine; Miszkiel, Katherine; Khan, Omar; Rice, George; Sheremata, William; Barker, G. J.; MacManus, D. G.; Webb, C.; Middleditch, C.; Lewis, S.; Pepple, T.; Riddle, E.; Coombs, C.; Agius, M.; Richman, D.; Adams, J.; Buonocore, M.; Al-Omaishi, J.; Markopoulou, K.; Healey, K.; Sorensen, P.; Bates, D.; Forsyth, J.; Curlis, J.; English, P.; Blumhardt, L.; Orpe, V.; Jaspen, T.; Bowen, J.; Chang, M.; Lew, H.; Burke, M.; Richards, T.; Carter, J. L.; Dodick, D.; Takata, J.; Malikowski, M.; Nelson, K.; Cross, D. A H; Trotter, J.; Derrington, D.; Lauber, J.; Martinez, C.; Foster, G.; Conturo, T.; Devonshire, V.; Oger, J.; Wang, L.; Morrison, W.; Costley, L.; Hawkins, C.; Mathews, C.; Gibson, C.; Hebert, J.; Rozentsvit, I.; Capolino, L.; Kelly, J. P.; Kaufman, M.; Putman, S.; Diedrich, A.; Follmer, R.; Dombrowski, S.; Graves, C.; Harwick, B.; Tselis, A. C.; Din, M.; Caon, C.; Cochran, M.; Latif, Z.; Lisak, R. P.; Zvartau-Hinds, M.; Metz, L.; Scott, J.; Patry, D.; Yeung, M.; Heuser, J.; Wallace, C.; Curtis, S.; Miller, A.; Drexler, E.; Keilson, M. J.; Bruining, K.; Schneider, A.; Wolintz, R.; Sciarra, L.; Oltazewska, H.; Murray, R. S.; Bowling, A.; Kramer, R. E.; Bracht, K.; O'Brien, C.; Seeberger, L.; Leitch, J.; Prenger, E.

In: Multiple Sclerosis, Vol. 11, No. 5, 01.10.2005, p. 568-572.

Research output: Contribution to journalArticle

O'Connor, P, Miller, D, Riester, K, Yang, M, Panzara, M, Dalton, C, Miszkiel, K, Khan, O, Rice, G, Sheremata, W, Barker, GJ, MacManus, DG, Webb, C, Middleditch, C, Lewis, S, Pepple, T, Riddle, E, Coombs, C, Agius, M, Richman, D, Adams, J, Buonocore, M, Al-Omaishi, J, Markopoulou, K, Healey, K, Sorensen, P, Bates, D, Forsyth, J, Curlis, J, English, P, Blumhardt, L, Orpe, V, Jaspen, T, Bowen, J, Chang, M, Lew, H, Burke, M, Richards, T, Carter, JL, Dodick, D, Takata, J, Malikowski, M, Nelson, K, Cross, DAH, Trotter, J, Derrington, D, Lauber, J, Martinez, C, Foster, G, Conturo, T, Devonshire, V, Oger, J, Wang, L, Morrison, W, Costley, L, Hawkins, C, Mathews, C, Gibson, C, Hebert, J, Rozentsvit, I, Capolino, L, Kelly, JP, Kaufman, M, Putman, S, Diedrich, A, Follmer, R, Dombrowski, S, Graves, C, Harwick, B, Tselis, AC, Din, M, Caon, C, Cochran, M, Latif, Z, Lisak, RP, Zvartau-Hinds, M, Metz, L, Scott, J, Patry, D, Yeung, M, Heuser, J, Wallace, C, Curtis, S, Miller, A, Drexler, E, Keilson, MJ, Bruining, K, Schneider, A, Wolintz, R, Sciarra, L, Oltazewska, H, Murray, RS, Bowling, A, Kramer, RE, Bracht, K, O'Brien, C, Seeberger, L, Leitch, J & Prenger, E 2005, 'Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis', Multiple Sclerosis, vol. 11, no. 5, pp. 568-572. https://doi.org/10.1191/1352458505ms1205oa
O'Connor, Paul ; Miller, David ; Riester, Katherine ; Yang, Minhua ; Panzara, Michael ; Dalton, Catherine ; Miszkiel, Katherine ; Khan, Omar ; Rice, George ; Sheremata, William ; Barker, G. J. ; MacManus, D. G. ; Webb, C. ; Middleditch, C. ; Lewis, S. ; Pepple, T. ; Riddle, E. ; Coombs, C. ; Agius, M. ; Richman, D. ; Adams, J. ; Buonocore, M. ; Al-Omaishi, J. ; Markopoulou, K. ; Healey, K. ; Sorensen, P. ; Bates, D. ; Forsyth, J. ; Curlis, J. ; English, P. ; Blumhardt, L. ; Orpe, V. ; Jaspen, T. ; Bowen, J. ; Chang, M. ; Lew, H. ; Burke, M. ; Richards, T. ; Carter, J. L. ; Dodick, D. ; Takata, J. ; Malikowski, M. ; Nelson, K. ; Cross, D. A H ; Trotter, J. ; Derrington, D. ; Lauber, J. ; Martinez, C. ; Foster, G. ; Conturo, T. ; Devonshire, V. ; Oger, J. ; Wang, L. ; Morrison, W. ; Costley, L. ; Hawkins, C. ; Mathews, C. ; Gibson, C. ; Hebert, J. ; Rozentsvit, I. ; Capolino, L. ; Kelly, J. P. ; Kaufman, M. ; Putman, S. ; Diedrich, A. ; Follmer, R. ; Dombrowski, S. ; Graves, C. ; Harwick, B. ; Tselis, A. C. ; Din, M. ; Caon, C. ; Cochran, M. ; Latif, Z. ; Lisak, R. P. ; Zvartau-Hinds, M. ; Metz, L. ; Scott, J. ; Patry, D. ; Yeung, M. ; Heuser, J. ; Wallace, C. ; Curtis, S. ; Miller, A. ; Drexler, E. ; Keilson, M. J. ; Bruining, K. ; Schneider, A. ; Wolintz, R. ; Sciarra, L. ; Oltazewska, H. ; Murray, R. S. ; Bowling, A. ; Kramer, R. E. ; Bracht, K. ; O'Brien, C. ; Seeberger, L. ; Leitch, J. ; Prenger, E. / Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis. In: Multiple Sclerosis. 2005 ; Vol. 11, No. 5. pp. 568-572.
@article{501354cdfbdc4a9cbb7f9d887e052f57,
title = "Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis",
abstract = "Background: Natalizumab, a humanized monoclonal IgG4 antibody, is an α4-integrin antagonist, which inhibits the migration of inflammatory cells into the central nervous system, a key pathogenic mechanism in multiple sclerosis (MS). In a six month, phase II clinical trial of patients with relapsing MS, natalizumab significantly reduced the formation of new gadolinium-enhanced (Gd+) lesions and the number of clinical relapses. Objective: To investigate the relationship of historical relapse rate and new Gd+ lesion number with subsequent MS disease activity and natalizumab treatment in the phase II study. Methods: Patients who participated in the phase II study were stratified into subgroups according to: (i) the number of relapses in the two years prior to entry into the study: 2 relapses (n = 108), 3 relapses (n = 57), and >3 relapses (n = 48); (ii) the number of new Gd+ lesions at baseline (Month 0): 0 (n = 129), 1-2 (n = 50), and >2 (n = 33). Relapses and new Gd+ lesions during the treatment phase of the trial were determined and compared for each subgroup. Results: Both the prestudy relapse rate and number of new Gd+ lesions at baseline were related to the subsequent risk of a relapse; baseline number of Gd+ lesions was related to the likelihood of subsequent new Gd+ lesion formation. There was a lower proportion of subjects with an on-study relapse and fewer new Gd+ lesions in all natalizumab-treated subgroups when compared with their placebo counterpart; the difference was most apparent in the subgroups of patients with >3 relapses in the two years prior to study entry and >2 new Gd+ lesions at Month 0. Conclusions: There was a lower proportion of subjects with an on-study relapse in natalizumab-treated patients, particularly in those with a more active disease at study entry. Larger ongoing phase III studies will allow more definitive investigation of these preliminary subgroup findings.",
keywords = "Gadolinium-enhancing lesions, Natalizumab, Relapsing MS",
author = "Paul O'Connor and David Miller and Katherine Riester and Minhua Yang and Michael Panzara and Catherine Dalton and Katherine Miszkiel and Omar Khan and George Rice and William Sheremata and Barker, {G. J.} and MacManus, {D. G.} and C. Webb and C. Middleditch and S. Lewis and T. Pepple and E. Riddle and C. Coombs and M. Agius and D. Richman and J. Adams and M. Buonocore and J. Al-Omaishi and K. Markopoulou and K. Healey and P. Sorensen and D. Bates and J. Forsyth and J. Curlis and P. English and L. Blumhardt and V. Orpe and T. Jaspen and J. Bowen and M. Chang and H. Lew and M. Burke and T. Richards and Carter, {J. L.} and D. Dodick and J. Takata and M. Malikowski and K. Nelson and Cross, {D. A H} and J. Trotter and D. Derrington and J. Lauber and C. Martinez and G. Foster and T. Conturo and V. Devonshire and J. Oger and L. Wang and W. Morrison and L. Costley and C. Hawkins and C. Mathews and C. Gibson and J. Hebert and I. Rozentsvit and L. Capolino and Kelly, {J. P.} and M. Kaufman and S. Putman and A. Diedrich and R. Follmer and S. Dombrowski and C. Graves and B. Harwick and Tselis, {A. C.} and M. Din and C. Caon and M. Cochran and Z. Latif and Lisak, {R. P.} and M. Zvartau-Hinds and L. Metz and J. Scott and D. Patry and M. Yeung and J. Heuser and C. Wallace and S. Curtis and A. Miller and E. Drexler and Keilson, {M. J.} and K. Bruining and A. Schneider and R. Wolintz and L. Sciarra and H. Oltazewska and Murray, {R. S.} and A. Bowling and Kramer, {R. E.} and K. Bracht and C. O'Brien and L. Seeberger and J. Leitch and E. Prenger",
year = "2005",
month = "10",
day = "1",
doi = "10.1191/1352458505ms1205oa",
language = "English",
volume = "11",
pages = "568--572",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis

AU - O'Connor, Paul

AU - Miller, David

AU - Riester, Katherine

AU - Yang, Minhua

AU - Panzara, Michael

AU - Dalton, Catherine

AU - Miszkiel, Katherine

AU - Khan, Omar

AU - Rice, George

AU - Sheremata, William

AU - Barker, G. J.

AU - MacManus, D. G.

AU - Webb, C.

AU - Middleditch, C.

AU - Lewis, S.

AU - Pepple, T.

AU - Riddle, E.

AU - Coombs, C.

AU - Agius, M.

AU - Richman, D.

AU - Adams, J.

AU - Buonocore, M.

AU - Al-Omaishi, J.

AU - Markopoulou, K.

AU - Healey, K.

AU - Sorensen, P.

AU - Bates, D.

AU - Forsyth, J.

AU - Curlis, J.

AU - English, P.

AU - Blumhardt, L.

AU - Orpe, V.

AU - Jaspen, T.

AU - Bowen, J.

AU - Chang, M.

AU - Lew, H.

AU - Burke, M.

AU - Richards, T.

AU - Carter, J. L.

AU - Dodick, D.

AU - Takata, J.

AU - Malikowski, M.

AU - Nelson, K.

AU - Cross, D. A H

AU - Trotter, J.

AU - Derrington, D.

AU - Lauber, J.

AU - Martinez, C.

AU - Foster, G.

AU - Conturo, T.

AU - Devonshire, V.

AU - Oger, J.

AU - Wang, L.

AU - Morrison, W.

AU - Costley, L.

AU - Hawkins, C.

AU - Mathews, C.

AU - Gibson, C.

AU - Hebert, J.

AU - Rozentsvit, I.

AU - Capolino, L.

AU - Kelly, J. P.

AU - Kaufman, M.

AU - Putman, S.

AU - Diedrich, A.

AU - Follmer, R.

AU - Dombrowski, S.

AU - Graves, C.

AU - Harwick, B.

AU - Tselis, A. C.

AU - Din, M.

AU - Caon, C.

AU - Cochran, M.

AU - Latif, Z.

AU - Lisak, R. P.

AU - Zvartau-Hinds, M.

AU - Metz, L.

AU - Scott, J.

AU - Patry, D.

AU - Yeung, M.

AU - Heuser, J.

AU - Wallace, C.

AU - Curtis, S.

AU - Miller, A.

AU - Drexler, E.

AU - Keilson, M. J.

AU - Bruining, K.

AU - Schneider, A.

AU - Wolintz, R.

AU - Sciarra, L.

AU - Oltazewska, H.

AU - Murray, R. S.

AU - Bowling, A.

AU - Kramer, R. E.

AU - Bracht, K.

AU - O'Brien, C.

AU - Seeberger, L.

AU - Leitch, J.

AU - Prenger, E.

PY - 2005/10/1

Y1 - 2005/10/1

N2 - Background: Natalizumab, a humanized monoclonal IgG4 antibody, is an α4-integrin antagonist, which inhibits the migration of inflammatory cells into the central nervous system, a key pathogenic mechanism in multiple sclerosis (MS). In a six month, phase II clinical trial of patients with relapsing MS, natalizumab significantly reduced the formation of new gadolinium-enhanced (Gd+) lesions and the number of clinical relapses. Objective: To investigate the relationship of historical relapse rate and new Gd+ lesion number with subsequent MS disease activity and natalizumab treatment in the phase II study. Methods: Patients who participated in the phase II study were stratified into subgroups according to: (i) the number of relapses in the two years prior to entry into the study: 2 relapses (n = 108), 3 relapses (n = 57), and >3 relapses (n = 48); (ii) the number of new Gd+ lesions at baseline (Month 0): 0 (n = 129), 1-2 (n = 50), and >2 (n = 33). Relapses and new Gd+ lesions during the treatment phase of the trial were determined and compared for each subgroup. Results: Both the prestudy relapse rate and number of new Gd+ lesions at baseline were related to the subsequent risk of a relapse; baseline number of Gd+ lesions was related to the likelihood of subsequent new Gd+ lesion formation. There was a lower proportion of subjects with an on-study relapse and fewer new Gd+ lesions in all natalizumab-treated subgroups when compared with their placebo counterpart; the difference was most apparent in the subgroups of patients with >3 relapses in the two years prior to study entry and >2 new Gd+ lesions at Month 0. Conclusions: There was a lower proportion of subjects with an on-study relapse in natalizumab-treated patients, particularly in those with a more active disease at study entry. Larger ongoing phase III studies will allow more definitive investigation of these preliminary subgroup findings.

AB - Background: Natalizumab, a humanized monoclonal IgG4 antibody, is an α4-integrin antagonist, which inhibits the migration of inflammatory cells into the central nervous system, a key pathogenic mechanism in multiple sclerosis (MS). In a six month, phase II clinical trial of patients with relapsing MS, natalizumab significantly reduced the formation of new gadolinium-enhanced (Gd+) lesions and the number of clinical relapses. Objective: To investigate the relationship of historical relapse rate and new Gd+ lesion number with subsequent MS disease activity and natalizumab treatment in the phase II study. Methods: Patients who participated in the phase II study were stratified into subgroups according to: (i) the number of relapses in the two years prior to entry into the study: 2 relapses (n = 108), 3 relapses (n = 57), and >3 relapses (n = 48); (ii) the number of new Gd+ lesions at baseline (Month 0): 0 (n = 129), 1-2 (n = 50), and >2 (n = 33). Relapses and new Gd+ lesions during the treatment phase of the trial were determined and compared for each subgroup. Results: Both the prestudy relapse rate and number of new Gd+ lesions at baseline were related to the subsequent risk of a relapse; baseline number of Gd+ lesions was related to the likelihood of subsequent new Gd+ lesion formation. There was a lower proportion of subjects with an on-study relapse and fewer new Gd+ lesions in all natalizumab-treated subgroups when compared with their placebo counterpart; the difference was most apparent in the subgroups of patients with >3 relapses in the two years prior to study entry and >2 new Gd+ lesions at Month 0. Conclusions: There was a lower proportion of subjects with an on-study relapse in natalizumab-treated patients, particularly in those with a more active disease at study entry. Larger ongoing phase III studies will allow more definitive investigation of these preliminary subgroup findings.

KW - Gadolinium-enhancing lesions

KW - Natalizumab

KW - Relapsing MS

UR - http://www.scopus.com/inward/record.url?scp=25844462420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25844462420&partnerID=8YFLogxK

U2 - 10.1191/1352458505ms1205oa

DO - 10.1191/1352458505ms1205oa

M3 - Article

C2 - 16193895

AN - SCOPUS:25844462420

VL - 11

SP - 568

EP - 572

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 5

ER -